Ferring and Evotec to create a research alliance in reproductive medicine

18 October 2018

GMP News

Ferring Pharmaceuticals and Evotec AG announced a strategic research alliance to discover and develop new small molecule therapies to treat patients living with fertility and gynaecological conditions.

Evotec will apply its drug discovery platform to design novel and efficacious treatments in partnership with Ferring. The multi-target, multi-year collaboration aims to deliver small molecule pre-clinical development (PDC) and investigational new drug (IND) ready candidates. As part of the alliance, Evotec is eligible for undisclosed research funding and milestones.

Headquartered in Saint-Prex (Switzerland), Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group. The company became a leader in reproductive medicine and women’s health, and in specialty areas within gastroenterology and urology.

Based in Hamburg (Germany), Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists.

Source

Print

Shareholders

Read more

Pipeline

Read more

Media Center

Read more